ABCL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ABCL is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has some positive analyst support and a very strong revenue growth quarter, but the latest price action is weak, there is no Intellectia buy signal, and profitability remains negative. For an impatient investor who does not want to wait for a better entry, this is still a hold rather than a buy.
ABCL closed at 4.90 after a 4.37% regular-session decline, which is below the previous close of 5.04. The MACD histogram is positive at 0.0838 but contracting, suggesting momentum is fading rather than strengthening. RSI_6 at 69.405 is near the upper end of neutral and close to overbought territory. Moving averages are converging, which usually points to a sideways or indecisive trend. Key levels show resistance at 5.03 and 5.38, with support at 4.47 and 3.90. Overall, the technical setup is mixed to weak in the very near term, with no confirmed bullish breakout.
["Cantor Fitzgerald initiated coverage with Overweight and a $7 target.", "JonesResearch initiated coverage with Buy and an $11 target.", "Revenue in 2025/Q4 increased sharply year over year by 788.18%.", "Gross margin remained at 100%, showing strong unit economics at the gross profit level.", "Options positioning is call-heavy, indicating bullish trader sentiment.", "Earnings are scheduled for 2026-05-11 after hours, which can act as a near-term catalyst."]
["No news in the last week, so there is no fresh catalyst from recent headlines.", "Net income remained negative at -8.945M in 2025/Q4.", "EPS was still negative at -0.03.", "The stock fell 4.37% in the regular session, showing weak current price action.", "AI Stock Picker shows no signal today.", "SwingMax shows no recent signal.", "Hedge funds and insiders are both neutral with no meaningful recent buying activity.", "No congress trading data is available."]
In 2025/Q4, AbCellera delivered a major revenue jump to 44.853M, up 788.18% year over year, which is the clearest positive in the latest quarter. However, profitability remains weak: net income was -8.945M and EPS was -0.03, both worse year over year. Gross margin was 100%, indicating strong gross economics, but the company is still not generating bottom-line profit. The latest quarter therefore shows fast top-line growth but continued losses.
Analyst sentiment has improved recently. On 2026-05-05, Cantor Fitzgerald initiated coverage with an Overweight rating and a $7 target. On 2026-04-09, JonesResearch initiated coverage with a Buy rating and an $11 target. This is a constructive analyst trend with two positive initiations and reasonably bullish price targets. Wall Street pros appear to see upside in the antibody discovery platform, but the market has not yet fully confirmed that optimism in price action.
